• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCoronavirus

With a new vaccine and fast-spreading variants, U.S. COVID fight becomes a head-to-head race

By
David Z. Morris
David Z. Morris
Down Arrow Button Icon
By
David Z. Morris
David Z. Morris
Down Arrow Button Icon
March 1, 2021, 5:09 PM ET

An imminent surge in vaccine supply suggests that the United States is on the verge of making huge strides against the coronavirus pandemic. But experts say getting those doses into arms as quickly as possible over the next few weeks, while controlling the spread of the virus, will be crucial to tackling the biggest risk on the horizon: a proliferating array of COVID-19 variants, some of them more dangerous than the currently dominant strain, which could fuel a fourth pandemic surge.

“This is a race against time,” said Jennifer Kates, director of global health at KFF (formerly the Kaiser Family Foundation). “If we don’t see any further case surges, and vaccination continues to increase, we will likely get ahead of the variants—this is the winning combo. However, we could ‘lose’ if we open too quickly, vaccinate too slowly, and the variants therefore can take greater hold.”

CDC director Rochelle Walensky gave an even starker warning during a White House pandemic briefing on Monday. After a sharp and long decline in case counts since early January, Walensky said that “we stand to completely lose the hard-earned ground we have gained” against the coronavirus if relaxed safety standards or disruption in the vaccine rollout gives variants time to gain the upper hand.

There is already some sign that recent positive trends are reversing, with the current seven-day rolling average of new cases currently up 2% from a week ago.

The White House says 3.9 million doses of Johnson & Johnson’s COVID-19 vaccine, which received emergency approval from the FDA over the weekend, will be distributed across the country this week. Vaccinations are expected to begin on Tuesday, March 2. That should mean a major expansion over the 13.5 million doses of vaccines from Pfizer and Moderna delivered to states and pharmacies in recent weeks. Johnson & Johnson expects a slight dip in deliveries in the middle of the month, according to White House COVID czar Andy Slavitt, but expects to deliver a total of 20 million doses by the end of March.

That would be a further boost to a vaccination effort that President Joe Biden says is already “weeks ahead of schedule” (though that’s against a timeline that some critics have said wasn’t ambitious enough). KFF estimates that enough doses to vaccinate 130 million Americans will be delivered to states by the end of March.

“The J&J vaccine will be an important contributor to the U.S. (and other countries) being able to bring an ‘end’ to the pandemic,” said Joshua Michaud, a health policy expert also with KFF.

But the surge in vaccine supplies comes as nearly a half-dozen variants of the coronavirus gain a foothold within the United States. Most if not all of them appear to respond well to existing vaccines, but initial studies suggest that several are more infectious, and some may be more deadly.

Most worrisome is the U.K. COVID-19 variant, scientifically known as B.1.1.7. There is a quickly emerging scientific consensus that the variant is more infectious than the primary strain. Research published early in February projected the U.K. variant would become the dominant strain by the end of March. Some research has also shown the U.K. variant to be more likely to kill those it infects.

Other variants also pose threats. A variant first detected in California, known as CAL.2C, may also be more virulent and deadly. It surged from 0% to 50% of California’s COVID-19 cases between September 2020 and January of this year.

The good news is that both the California and U.K. variants appear to respond well to current vaccines.

Other variants may have slightly more ability to evade vaccine protections. The Pfizer vaccine is slightly less effective against a variant from South Africa, which has reached 13 states. A New York variant known as B.1.526 and a Brazilian variant known as P.1—still rare in the U.S.—may have similar resistance.

Despite those worries, experts agree that widespread vaccination is crucial to controlling the variants before their increased infectiousness creates a fourth wave of viral surge. Walensky and others have also emphasized that loosening social distancing and other pandemic controls could make that fourth wave more likely, but states—including New York—are easing those controls anyway.

Finally, Dr. Anthony Fauci warned on Monday that faster vaccination is essential to preventing the emergence of even more variants. That’s because the virus can mutate within individual carriers, especially immunocompromised patients.

Getting vaccinated is “not only important for [patients’] own health, but that could be the breeding ground of the emergence of variants,” said Fauci. “If you don’t clear the virus rapidly, you’re going to have immunological selection within a given individual. And that was probably how all this started with 526.”

About the Author
By David Z. Morris
See full bioRight Arrow Button Icon

Latest in Health

Workplace CultureSports
Exclusive: Billionaire Michele Kang launches $25 million U.S. Soccer institute that promises to transform the future of women’s sports
By Emma HinchliffeDecember 2, 2025
9 hours ago
North Americaphilanthropy
Anonymous $50 million donation helps cover the next 50 years of tuition for medical lab science students at University of Washington
By The Associated PressDecember 2, 2025
15 hours ago
Trump
PoliticsWhite House
Trump had MRI on heart and abdomen and it was ‘perfectly normal,’ doctor says
By The Associated PressDecember 2, 2025
15 hours ago
Medical Glasses
InnovationNews
New FDA-approved glasses can slow nearsightedness in kids
By The Associated Press and Matthew PerroneDecember 1, 2025
1 day ago
Luigi Mangione
LawNews
Luigi Mangione watches footage of cops approaching him at Altoona McDonald’s as courtroom hearings commence
By Michael R. Sisak and The Associated PressDecember 1, 2025
1 day ago
Our testers trying out a Nectar mattress.
Healthmattresses
Best Cyber Monday Mattress Deals of 2025: Saatva, Helix, and More
By Christina SnyderDecember 1, 2025
2 days ago

Most Popular

placeholder alt text
Economy
Ford workers told their CEO 'none of the young people want to work here.' So Jim Farley took a page out of the founder's playbook
By Sasha RogelbergNovember 28, 2025
4 days ago
placeholder alt text
Success
Warren Buffett used to give his family $10,000 each at Christmas—but when he saw how fast they were spending it, he started buying them shares instead
By Eleanor PringleDecember 2, 2025
17 hours ago
placeholder alt text
Economy
Elon Musk says he warned Trump against tariffs, which U.S. manufacturers blame for a turn to more offshoring and diminishing American factory jobs
By Sasha RogelbergDecember 2, 2025
11 hours ago
placeholder alt text
C-Suite
MacKenzie Scott's $19 billion donations have turned philanthropy on its head—why her style of giving actually works
By Sydney LakeDecember 2, 2025
18 hours ago
placeholder alt text
Success
Forget the four-day workweek, Elon Musk predicts you won't have to work at all in ‘less than 20 years'
By Jessica CoacciDecember 1, 2025
1 day ago
placeholder alt text
AI
More than 1,000 Amazon employees sign open letter warning the company's AI 'will do staggering damage to democracy, our jobs, and the earth’
By Nino PaoliDecember 2, 2025
19 hours ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.